🇺🇸 RCUS — Arcus Biosciences, Inc.

Salud Compra fuerte
← Volver

Precio actual

19,31 USD

Máx. histórico

48,47

1807 días

Caída desde máximo

-60,16%

Rango 52 semanas

17,43 – 31,74

Variación hoy

+2,12%

Cierre anterior

18,91

Rango de hoy

18,60 – 19,61

Volumen hoy

2.076.185

Peor caída histórica

-85,83%

23/11/2021 → 04/04/2025

Aún sin recuperar

Volatilidad anualizada ⓘ

75,61%

Información
Nombre completo
Arcus Biosciences, Inc.
Divisa
USD
Mercado
NYSE
Sector
Salud
Industria
Biotechnology
Empleados
601
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
41,00 USD (puede no estar actualizado)
Primera cotización
15/03/2018
Precio actualizado
hace 16 horas
Sobre la empresa

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC; BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases; and Bristol-Myers Squibb Company to develop a novel treatment regimen that delivers tumor control in kidney cancer. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
08/07/2020 25,42 25,84 24,29 25,28 -0,16% 6,09% 655.700
07/07/2020 23,90 25,57 23,82 25,32 +5,37% 7,32% 625.600
06/07/2020 24,82 24,99 23,48 24,03 -0,08% 6,08% 880.200
02/07/2020 23,61 24,14 22,52 24,05 +2,87% 6,88% 775.100
01/07/2020 24,80 24,90 22,80 23,38 -5,50% 8,47% 1.084.500
30/06/2020 23,77 25,46 23,46 24,74 +4,70% 8,41% 706.900
29/06/2020 22,95 23,72 22,16 23,63 +3,82% 6,82% 949.800
26/06/2020 24,06 24,58 22,73 22,76 -6,18% 7,69% 1.682.900
25/06/2020 23,99 24,76 23,25 24,26 +0,37% 6,30% 843.100
24/06/2020 24,86 25,35 23,92 24,17 -3,55% 5,75% 994.900
23/06/2020 26,12 26,31 24,93 25,06 -3,06% 5,28% 926.000
22/06/2020 26,07 26,48 25,28 25,85 -0,84% 4,60% 996.200
19/06/2020 27,50 28,03 25,89 26,07 -5,20% 7,78% 2.319.900
18/06/2020 27,44 28,61 27,24 27,50 -0,51% 4,99% 552.800
17/06/2020 29,09 29,12 27,54 27,64 -4,23% 5,43% 461.600
16/06/2020 29,73 30,00 28,24 28,86 -1,64% 5,92% 612.600
15/06/2020 27,15 29,51 27,11 29,34 +5,46% 8,84% 554.800
12/06/2020 28,31 28,70 26,97 27,82 +0,87% 6,11% 819.500
11/06/2020 28,88 29,30 27,55 27,58 -6,95% 6,06% 708.300
10/06/2020 30,33 30,46 28,81 29,64 +0,24% 5,44% 596.000
09/06/2020 28,85 30,09 28,24 29,57 +2,11% 6,43% 499.800
08/06/2020 28,71 29,38 28,25 28,96 -0,31% 3,95% 639.000
05/06/2020 30,67 30,70 28,08 29,05 -3,33% 8,56% 897.400
04/06/2020 30,79 31,14 29,75 30,05 -3,69% 4,51% 521.100
03/06/2020 34,91 34,94 30,85 31,20 -9,62% 11,72% 911.000
02/06/2020 33,29 35,39 33,22 34,52 +4,48% 6,52% 748.300
01/06/2020 31,18 34,49 30,35 33,04 +5,39% 13,28% 2.427.300
29/05/2020 29,25 32,48 28,37 31,35 +11,13% 14,05% 3.426.800
28/05/2020 26,99 29,85 26,72 28,21 +4,29% 11,60% 1.486.100
27/05/2020 28,54 30,89 26,58 27,05 -19,35% 15,10% 2.430.100